Impact News +++ Circle Stock Enters Oversold Territory on Earnings Plunge. Should You Buy the Dip? (Barchart) +++ CIRCLE INTERNET Aktie -3,14%

TALPHERA Aktie

>TALPHERA Aktienkurs

1.117 EUR (Tradegate)

Ask: 1.132 EUR / 1400 Stück

Bid: 1.102 EUR / 1400 Stück

Tagesumsatz: 0 Stück

Realtime Kurs von 7:30 bis 22 Uhr!

TALPHERA Aktie über LYNX handeln

Intraday

1 Jahr

>TALPHERA Performance

1 Woche: -0,2%

1 Monat: +5,1%

3 Monate: +211,1%

6 Monate: +137,2%

1 Jahr: +33,3%

laufendes Jahr: +118,3%

>TALPHERA Aktie

Name:

TALPHERA INC. DL-,01

Land:

USA

Sektor:

Gesundheit

ISIN/ Wkn:

US00444T2096 / A3DWPN

Symbol/ Ticker:

R5XA (Frankfurt) / TLPH (NASDAQ)

Kürzel:

FRA:R5XA, ETR:R5XA, R5XA:GR, NASDAQ:TLPH

Index:

Webseite:

https://talphera.com/

Profil:

Talphera Inc. is a dynamic entity in the competiti..
>Volltext..

Marktkapitalisierung:

51.99 Mio. EUR

Unternehmenswert:

51.74 Mio. EUR

Umsatz:

0.02 Mio. EUR

EBITDA:

-11.55 Mio. EUR

Nettogewinn:

-9.77 Mio. EUR

Gewinn je Aktie:

-0.34 EUR

Schulden:

5.62 Mio. EUR

Liquide Mittel:

5.87 Mio. EUR

Operativer Cashflow:

-10.04 Mio. EUR

Bargeldquote:

2.58

Umsatzwachstum:

-93.83%

Gewinnwachstum:

24.72%

Dividende je Aktie:

Dividendenrendite:

Dividendenschätzung:

Insiderhandel:

Suchwörter:

TALPHERA, ACELRX

Letzte Datenerhebung:

12.11.25

>TALPHERA Kennzahlen

Aktien/ Unternehmen:

Aktien: 46.61 Mio. St.

Frei handelbar: 70.95%

Leerverk. Aktien: 3.93%

Rückkaufquote: -7.28%

Mitarbeiter: 13

Umsatz/Mitarb.: -

Analysten:

Analystenrating: Strong buy

Kursziel: 156.19%

Bewertung:

KGV: -

KGV lG: -

KUV: 1504.85

KBV: 3.95

PEG-Ratio: -

EV/EBITDA: -

Rentabilität:

Bruttomarge: -

Gewinnmarge: -42140.74%

Operative Marge: -49459.26%

Managementeffizenz:

Gesamtkaprendite: -55%

Eigenkaprendite: -117.56%

>TALPHERA Peer Group

Es sind 597 Aktien bekannt.

>TALPHERA Chart & Kurs - NASDAQ

>TALPHERA News

12.11.25 - 22:06	Talphera Announces Third Quarter 2025 Financial Results and Provides Corporate Update (PR Newswire)
	Closed $17 million first tranche financing led by a strategic investment from CorMedix, Inc. Cash and investments at September 30, 2025 were $21.3 million; combined with conditional future tranches of previous financings, expect sufficient cash through a potential PMA approval of Niyad in......

05.11.25 - 22:06	Talphera to Host Third Quarter Financial Results and Corporate Update Call and Webcast on Wednesday, November 12, 2025 (PR Newswire)
	SAN MATEO, Calif., Nov. 5, 2025 /PRNewswire/ -- Talphera, Inc. (Nasdaq: TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced that it will release third......

21.10.25 - 14:33	Talphera Announces the Appointment of Joe Todisco to Board of Directors (PR Newswire)
	SAN MATEO, Calif., Oct. 21, 2025 /PRNewswire/ -- Talphera, Inc. (Nasdaq: TLPH), (Talphera), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced the appointment of Joe Todisco,......

22.09.25 - 23:24	Talphera files prospectus for resale of up to 30.9M shares by selling stockholders (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

08.09.25 - 14:54	Talphera announces private placement financing of up to $29M priced at-the market (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

08.09.25 - 14:33	Talphera Announces Private Placement Financing of up to $29 Million Priced At-the Market (PR Newswire)
	CorMedix is making a strategic investment in Talphera as the lead investor, supported by existing stockholders Nantahala, Rosalind and Rock Springs with several new institutional investors $17 million in proceeds at first closing with the potential to receive an additional $12 million......

08.09.25 - 14:33

CorMedix Announces Strategic Minority Investment in Talphera (GlobeNewswire EN)

BERKELEY HEIGHTS, N.J., Sept. 08, 2025 (GLOBE NEWSWIRE) -- CorMedix Inc. (“CorMedix”) (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced that it has made a $5 million strategic minority equity investment in Talphera, Inc. (Nasdaq: TLPH), acquiring 9,090,909 shares at an at-market price of $0.55 per share as part of Talphera's concurrently announced private placement financing. Talphera expects to use the proceeds of the equity financing to fund the completion of its ongoing Phase 3 registrational study for Niyad™ and for pre-launch preparations....

25.08.25 - 14:33	Talphera Announces Achievement of 17 Patient Enrollment Milestone in NEPHRO CRRT Pivotal Trial (PR Newswire)
	The NEPHRO CRRT pivotal trial has now reached approximately 25% enrollment, driven by the recent acceleration in the recruitment rate from new profile clinical sites On track for planned study completion by the end of 2025 SAN MATEO, Calif., Aug. 25, 2025 /PRNewswire/ -- Talphera, Inc.......

15.08.25 - 03:18	Talphera outlines accelerated NEPHRO enrollment and lowers 2025 cash operating expense guidance amid protocol shift (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

15.08.25 - 00:12	Talphera Cuts Expenses 14 Percent (Fool)
	Um den gesamten Artikel unter fool.com zu lesen, klicken Sie bitte auf die Überschrift...

14.08.25 - 23:48	Talphera Cuts Costs and Speeds Trial (Fool)
	Um den gesamten Artikel unter fool.com zu lesen, klicken Sie bitte auf die Überschrift...

14.08.25 - 23:48	Talphera TLPH Q2 2025 Earnings Call Transcript (Fool)
	Um den gesamten Artikel unter fool.com zu lesen, klicken Sie bitte auf die Überschrift...

14.08.25 - 22:09	Talphera GAAP EPS of -$0.10 beats by $0.03 (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

14.08.25 - 22:06	Talphera Announces Second Quarter 2025 Financial Results and Provides Corporate Update (PR Newswire)
	New sites accelerate registrational study enrollment - 15 patients have been enrolled in the NEPHRO study which remains on track with completion projected by the end of the year Cash and cash equivalents at June 30, 2025 were $6.8 million Conference call and webcast to be held Thursday,......

07.08.25 - 22:39	Talphera to Host Second Quarter Financial Results and Corporate Update Call and Webcast on Thursday, August 14, 2025 (PR Newswire)
	SAN MATEO, Calif., Aug. 7, 2025 /PRNewswire/ -- Talphera, Inc. (Nasdaq: TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced that it will release second......

15.05.25 - 03:06	Talphera outlines accelerated NEPHRO CRRT study timeline with completion targeted by end of 2025, supported by new site activations and $14.8M financing (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

14.05.25 - 22:12	Talphera GAAP EPS of -$0.10 beats by $0.05 (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

14.05.25 - 22:09	Talphera Announces First Quarter 2025 Financial Results and Provides Corporate Update (PR Newswire)
	Cash and investments at March 31, 2025, as adjusted to include the proceeds from the first tranche of the private placement financing which closed on April 2, 2025, were $9.8 million Three new clinical study sites activated and screening patients thus far in 2025, with five additional......

07.05.25 - 22:06	Talphera to Host First Quarter Financial Results and Corporate Update Call and Webcast on Wednesday, May 14, 2025 (PR Newswire)
	SAN MATEO, Calif., May 7, 2025 /PRNewswire/ -- Talphera, Inc. (Nasdaq: TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced that it will release first......

06.05.25 - 19:30	All You Need to Know About Talphera (TLPH) Rating Upgrade to Strong Buy (Zacks)
	Talphera (TLPH) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy)....

>weitere News anzeigen...

>Impressum >Über uns >Datenschutz >Financial Data & Solutions

>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!

Zitat des Tages: Die einzigen friedlichen Einfälle sind die des Geistes und des Lichtes. - Dr. Fritz P. Rinnhofer

Partner: >Tradegate Börse | >Dukascopy | >Boersentreff- Partner

Börsentreff auf Facebook |

Börsentreff auf X |

Börsentreff auf Instagram